Shrestha Malakh, Fischlein Theodore, Meuris Bart, Flameng Willem, Carrel Thierry, Madonna Francesco, Misfeld Martin, Folliguet Thierry, Haverich Axel, Laborde Francois
Cardio-thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
Klinikum Nuernberg, Paracelsus Medical University Nuremberg, Nuremberg, Germany.
Eur J Cardiothorac Surg. 2016 Jan;49(1):234-41. doi: 10.1093/ejcts/ezv040. Epub 2015 Mar 6.
This report summarizes the 5-year clinical and haemodynamic data from three prospective, European multicentre trials with the Perceval sutureless aortic valve.
From April 2007 to August 2012, 731 consecutive patients (mean age: 78.5 years; 68.1% females; mean logistic EuroSCORE 10.9%) underwent AVR with the Perceval valve in 25 European centres. Isolated AVR was performed in 498 (68.1%) patients. A minimally invasive approach was performed in 189 (25.9%) cases. The cumulative follow-up was 729 patients-years.
In isolated AVR, mean cross-clamp and cardiopulmonary bypass times were 30.8 and 50.8 min in full sternotomy, and 37.6 and 64.4 min in the minimally invasive approach, respectively. Early cardiac-related deaths occurred in 1.9%. Overall survival rates at 1 and 5 years were 92.1 and 74.7%, respectively. Major paravalvular leak occurred in 1.4% and 1% at early and late follow-up, respectively. Significant improvement in clinical status was observed postoperatively in the majority of patients. Mean and peak gradients decreased from 42.9 and 74.0 mmHg preoperatively, to 7.8 and 16 mmHg at the 3-year follow-up. LV mass decreased from 254.5 to 177.4 g at 3 years.
This European multicentre experience, with the largest cohort of patients with sutureless valves to date, shows excellent clinical and haemodynamic results that remain stable even up to the 5-year follow-up. Even in this elderly patient cohort with 40% octogenarians, both early and late mortality rates were very low. There were no valve migrations, structural valve degeneration or valve thrombosis in the follow-up. The sutureless technique is a promising alternative to biological aortic valve replacement.
本报告总结了三项关于Perceval无缝合主动脉瓣膜的欧洲前瞻性多中心试验的5年临床和血流动力学数据。
2007年4月至2012年8月,731例连续患者(平均年龄:78.5岁;68.1%为女性;平均逻辑欧洲心脏手术风险评估系统评分为10.9%)在25个欧洲中心接受了使用Perceval瓣膜的主动脉瓣置换术(AVR)。498例(68.1%)患者接受了单纯AVR。189例(25.9%)采用了微创方法。累计随访729患者年。
在单纯AVR中,全胸骨切开术的平均主动脉阻断和体外循环时间分别为30.8分钟和50.8分钟,微创方法分别为37.6分钟和64.4分钟。早期心脏相关死亡率为1.9%。1年和5年的总生存率分别为92.1%和74.7%。早期和晚期随访时,主要瓣周漏分别发生在1.4%和1%。大多数患者术后临床状况有显著改善。平均压差和峰值压差从术前的42.9 mmHg和74.0 mmHg降至3年随访时的7.8 mmHg和16 mmHg。左心室质量在3年时从254.5克降至177.4克。
这项欧洲多中心经验,是迄今为止无缝合瓣膜患者队列最大的,显示出优异的临床和血流动力学结果,甚至在5年随访时仍保持稳定。即使在这个80岁及以上患者占40%的老年患者队列中,早期和晚期死亡率都非常低。随访中无瓣膜移位、结构性瓣膜退变或瓣膜血栓形成。无缝合技术是生物主动脉瓣置换的一种有前景的替代方法。